A detailed history of Retirement Planning CO Of New England, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Retirement Planning CO Of New England, Inc. holds 22,443 shares of SUPN stock, worth $795,155. This represents 0.36% of its overall portfolio holdings.

Number of Shares
22,443
Previous 23,570 4.78%
Holding current value
$795,155
Previous $630,000 10.95%
% of portfolio
0.36%
Previous 0.35%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$25.77 - $35.16 $29,042 - $39,625
-1,127 Reduced 4.78%
22,443 $699,000
Q2 2024

Aug 08, 2024

SELL
$25.99 - $33.85 $50,264 - $65,465
-1,934 Reduced 7.58%
23,570 $630,000
Q1 2024

May 06, 2024

SELL
$27.11 - $35.17 $699,410 - $907,350
-25,799 Reduced 50.29%
25,504 $869,000
Q4 2023

Feb 12, 2024

SELL
$22.72 - $29.68 $6,929 - $9,052
-305 Reduced 0.59%
51,303 $1.48 Million
Q3 2023

Nov 13, 2023

BUY
$27.57 - $32.91 $652,195 - $778,518
23,656 Added 84.63%
51,608 $1.42 Million
Q2 2023

Aug 11, 2023

SELL
$29.91 - $38.73 $78,513 - $101,666
-2,625 Reduced 8.58%
27,952 $840,000
Q1 2023

Apr 21, 2023

SELL
$34.93 - $42.03 $79,011 - $95,071
-2,262 Reduced 6.89%
30,577 $1.11 Million
Q4 2022

Feb 03, 2023

SELL
$31.09 - $37.88 $12,591 - $15,341
-405 Reduced 1.22%
32,839 $1.17 Million
Q3 2022

Oct 19, 2022

SELL
$28.79 - $35.41 $116,599 - $143,410
-4,050 Reduced 10.86%
33,244 $1.13 Million
Q2 2022

Aug 12, 2022

SELL
$25.33 - $34.25 $17,097 - $23,118
-675 Reduced 1.78%
37,294 $1.08 Million
Q1 2022

May 06, 2022

BUY
$28.51 - $32.9 $13,912 - $16,055
488 Added 1.3%
37,969 $1.23 Million
Q4 2021

Feb 08, 2022

BUY
$26.37 - $34.22 $988,373 - $1.28 Million
37,481 New
37,481 $1.09 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Retirement Planning CO Of New England, Inc. Portfolio

Follow Retirement Planning CO Of New England, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Retirement Planning CO Of New England, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Retirement Planning CO Of New England, Inc. with notifications on news.